Full-Time

Head of Clinical Research

Metabolic Diseases

Confirmed live in the last 24 hours

Tessera Therapeutics

Tessera Therapeutics

201-500 employees

Develops gene editing technology for genetic medicine

Biotechnology
Healthcare

Expert

Cambridge, MA, USA

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Google Cloud Platform

You match the following Tessera Therapeutics's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • MD/PhD or equivalent degree with relevant internal medicine training and board certification
  • 15 years of industry experience in clinical development within a pharmaceutical or biotechnology company
  • Experience in designing, implementing, and overseeing multiple early-stage clinical studies
  • Direct experience with IND/CTA submissions
  • Thorough understanding of ICH and GCP guidelines
  • Understanding of clinical research methodology and biostatistics principles
  • Demonstrated track record of overseeing a clinical team and successfully completing clinical studies
  • Effective communication and presentation skills
Responsibilities
  • Providing clinical leadership and medical representation for the liver Gene WritingTM programs
  • Ensuring a streamlined and innovative clinical development and medical strategy
  • Authoring medical components for clinical development plans and associated documents
  • Hiring, developing and managing clinical development resources
  • Overseeing risk-based safety monitoring of clinical studies
  • Interpretation and analysis of clinical study safety and efficacy data
  • Preparation of meeting abstracts, posters, presentations, and publications
  • Maintaining a constant focus on patient wellbeing across the organization

Tessera Therapeutics focuses on genetic medicine, specifically through a technology called Gene Writing, which enables precise modifications to the human genome. This technology allows for permanent changes to genetic material in any cell, aiming to cure diseases at their source. Tessera's Gene Writing can perform both small and large genetic alterations, making it applicable to a wide range of genetic disorders. The company collaborates with research institutions, pharmaceutical companies, and healthcare providers to develop new treatments. Tessera generates revenue through partnerships, licensing agreements, and the potential sale of its technology. With significant funding secured, Tessera aims to advance its platform and fulfill its mission of curing diseases by rewriting genetic code.

Company Size

201-500

Company Stage

Series C

Total Funding

$518.2M

Headquarters

Cambridge, Massachusetts

Founded

2018

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Gates Foundation boosts development of sickle cell disease treatment.
  • $300 million Series C funding in 2022 supports platform advancement and commercialization.
  • Located in Boston, Tessera benefits from a thriving biotech ecosystem.

What critics are saying

  • Competition from CRISPR-based technologies may challenge Tessera's market position.
  • High development costs could delay Gene Writing technology's market entry.
  • Regulatory hurdles may slow approval and adoption of genetic therapies.

What makes Tessera Therapeutics unique

  • Tessera Therapeutics pioneers Gene Writing, a novel approach in genetic medicine.
  • Their technology allows precise genome alterations, surpassing traditional gene editing methods.
  • Tessera's platform targets a wide range of genetic disorders with versatile applications.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

0%

2 year growth

0%
DDW Online
Dec 18th, 2024
Investment to develop curative in vivo genetic treatment for sickle cell disease

Tessera Therapeutics, a biotech developing a new approach to genome engineering, has entered into an agreement with the Bill & Melinda Gates Foundation to jointly fund the company's in vivo programme for sickle cell disease (SCD).

BioSpace
Dec 18th, 2024
Tessera Therapeutics Receives Investment to Develop Curative In Vivo Genetic Treatment for Sickle Cell Disease

Tessera is developing Gene Writers(TM) for SCD designed to enable a true correction of the sickle mutation to wild-type with one-time intravenous administration in vivo, without the need for complex stem cell mobilization or toxic chemotherapy conditioning.

The Manila Times
Dec 18th, 2024
Tessera Therapeutics Receives Investment to Develop Curative In Vivo Genetic Treatment for Sickle Cell Disease

Tessera Therapeutics receives investment to develop curative in vivo genetic treatment for sickle cell disease.

Bizjournals
Dec 18th, 2024
Gates Foundation invests $50M in Tessera

The Bill & Melinda Gates Foundation is investing up to $50 million in Tessera Therapeutics to support its development of in-vivo genetic medicines for sickle cell disease. Tessera aims to offer a one-time intravenous treatment that avoids the need for high-dose chemotherapy and complex stem cell mobilization, unlike existing ex-vivo therapies. Tessera, founded by Flagship Pioneering, previously raised $230 million in Series B financing in 2021 and $300 million in 2022.

Labiotech
Oct 10th, 2024
12 Biotech Unicorns Revolutionizing The Future Of Healthcare

Have you ever heard of a biotech unicorn? Although a mythological creature might be what first springs to mind, a unicorn in the business world actually refers to a privately owned company valued at more than $1 billion. Some world-renowned former unicorns include Airbnb, Facebook, and Google. The reason they are called “unicorns” is because it is traditionally very rare for a company to achieve this valuation.In the biotech world, there are only a select few companies with unicorn status that are working on therapeutics. In this article, we take a closer look at 12 biotech unicorns rated in order of their valuations according to CB Insights.Table of contentsAbogen BiosciencesAbogen Biosciences is a Chinese biotech company and is valued at $3.7 billion. This comes as no surprise after it raised $700 million in series C funding back in August 2021, marking one of the largest private biotech funding rounds ever and obliterating the fundraising record for a Chinese mRNA vaccine developer. It then followed this round with another impressive series C+ round in November of the same year, in which it raised $300 million.Abogen is part of a rare breed of Chinese biotechs, having actually developed all of its key messenger RNA (mRNA) platform technologies itself, across mRNA synthesis, delivery, and manufacturing